91 related articles for article (PubMed ID: 8287777)
1. [Minimal heparinization in dialysis patients with increased risk of bleeding].
Klingel R; Wandel E; Hafner G; Meyer zum Büschenfelde KH; Köhler H
Dtsch Med Wochenschr; 1993 Dec; 118(51-52):1878-83. PubMed ID: 8287777
[TBL] [Abstract][Full Text] [Related]
2. [Prevention of thrombogenesis in the extracorporeal circuit of hemodialysis with a low molecular heparin: standardization of the dosage with a better hemorrhagic risk/effectiveness ratio].
Barata JD; Oliveira C; Bruges M; Gusmão L; Santana A; Ponce P; Simões J; Freire I; Crespo F; da Silva AN
Acta Med Port; 1992 Feb; 5(2):65-70. PubMed ID: 1317657
[TBL] [Abstract][Full Text] [Related]
3. Anticoagulant-free Genius haemodialysis using low molecular weight heparin-coated circuits.
Frank RD; Müller U; Lanzmich R; Groeger C; Floege J
Nephrol Dial Transplant; 2006 Apr; 21(4):1013-8. PubMed ID: 16326745
[TBL] [Abstract][Full Text] [Related]
4. Low molecular weight heparin and haemodialysis: neutralization by protaminchloride.
Andrassy K
Blood Coagul Fibrinolysis; 1993 Dec; 4 Suppl 1():S39-43. PubMed ID: 8180328
[TBL] [Abstract][Full Text] [Related]
5. [Complications and risks associated with an anticoagulation therapy combining low molecular weight heparin and Warfarin after total replacement of large joints--our experience].
Míka P; Behounek J; Skoták M; Nevsímal L
Acta Chir Orthop Traumatol Cech; 2004; 71(4):237-44. PubMed ID: 15456102
[TBL] [Abstract][Full Text] [Related]
6. Comparison of anticoagulation efficacy and clinical safety between imported and domestically manufactured low-molecular-weight heparin during hemodialysis.
Liu ZQ; Wang L
Di Yi Jun Yi Da Xue Xue Bao; 2002 Oct; 22(10):942-3. PubMed ID: 12377628
[TBL] [Abstract][Full Text] [Related]
7. [Clinical usefulness of Nephral ST dialyzers in hemodialyzed patients with increased risk of bleeding].
Kopeć J; Sułowicz W
Przegl Lek; 2010; 67(2):91-4. PubMed ID: 20557006
[TBL] [Abstract][Full Text] [Related]
8. [Therapeutic indications of low molecular weight heparins].
Samama MM; Michaut-Paterno F
Arch Mal Coeur Vaiss; 1991 Nov; 84(11 Suppl):1733-43. PubMed ID: 1662941
[TBL] [Abstract][Full Text] [Related]
9. Optimal anticoagulation strategy in haemodialysis with heparin-coated polyacrylonitrile membrane.
Lavaud S; Canivet E; Wuillai A; Maheut H; Randoux C; Bonnet JM; Renaux JL; Chanard J
Nephrol Dial Transplant; 2003 Oct; 18(10):2097-104. PubMed ID: 13679486
[TBL] [Abstract][Full Text] [Related]
10. [Intracranial hemorrhage and hemostasis. Monitoring patients after intracranial hemorrhage by determination and follow-up of activation products of blood coagulation].
Menges T; von Lessen A; Welters I; Wagner RM; Ruwoldt R; Boldt J; Hempelmann G
Infusionsther Transfusionsmed; 1994 Aug; 21(4):244-50. PubMed ID: 7950289
[TBL] [Abstract][Full Text] [Related]
11. [The use of enoxaparine for anticoagulation in extracorporeal circulation in hemodialysis at high risk for hemorrhage].
Dechelette E; Pouzol P; Jurkovitz C; Kuentz F; Polack B; Cuzin E; Woler M
J Mal Vasc; 1987; 12 Suppl B():105-7. PubMed ID: 2834479
[TBL] [Abstract][Full Text] [Related]
12. Systemic thrombin generation and activity resistant to low molecular weight heparin administered prior to streptokinase in patients with acute myocardial infarction.
Nilsen DW; Gøransson L; Larsen AI; Hetland O; Kierulf P
Thromb Haemost; 1997 Jan; 77(1):57-61. PubMed ID: 9031450
[TBL] [Abstract][Full Text] [Related]
13. Haemodialysis with low MW heparin: dosage requirements for the elimination of extracorporeal fibrin formation.
Lane DA; Ireland H; Flynn A; Anastassiades E; Curtis JR
Nephrol Dial Transplant; 1986; 1(3):179-87. PubMed ID: 2955253
[TBL] [Abstract][Full Text] [Related]
14. Rationale for the use of a low molecular weight heparin during hemodialysis with polysulphone membrane in uremic patients.
Moia M; Graziani G; Tenconi PM; Martinelli I; Ponticelli C
Ann Ital Med Int; 1997; 12(2):67-71. PubMed ID: 9284597
[TBL] [Abstract][Full Text] [Related]
15. Effects of a low molecular weight heparin (Fragmin) and of unfractionated heparin on coagulation activation at the site of plug formation in vivo.
Eichinger S; Wolz M; Nieszpaur-Los M; Schneider B; Lechner K; Eichler HG; Kyrle PA
Thromb Haemost; 1994 Dec; 72(6):831-5. PubMed ID: 7740450
[TBL] [Abstract][Full Text] [Related]
16. Low molecular weight heparin (dalteparin) is equally effective as unfractionated heparin in reducing coagulation activity and perfusion abnormalities during the early treatment of pulmonary embolism.
Schutgens RE; Esseboom EU; Snijder RJ; Haas FJ; Verzijlbergen F; Nieuwenhuis HK; Lisman T; Biesma DH
J Lab Clin Med; 2004 Aug; 144(2):100-7. PubMed ID: 15322504
[TBL] [Abstract][Full Text] [Related]
17. The correlation between plasma anti-factor Xa activity and haemostatic tests in healthy dogs, following the administration of a low molecular weight heparin.
Mischke R; Grebe S
Res Vet Sci; 2000 Dec; 69(3):241-7. PubMed ID: 11124095
[TBL] [Abstract][Full Text] [Related]
18. Clinical application of Fragmin (FR-860) in hemodialysis: multicenter cooperative study in Japan.
Suzuki T; Ota K; Naganuma S; Koshikawa S; Hirasawa Y; Nakagawa S; Otsubo O; Akizawa T
Semin Thromb Hemost; 1990 Oct; 16 Suppl():46-54. PubMed ID: 1962904
[TBL] [Abstract][Full Text] [Related]
19. Standard heparin versus low-molecular-weight heparin. A medium-term comparison in hemodialysis.
Stefoni S; Cianciolo G; Donati G; Colì L; La Manna G; Raimondi C; Dalmastri V; Orlandi V; D'Addio F
Nephron; 2002; 92(3):589-600. PubMed ID: 12372942
[TBL] [Abstract][Full Text] [Related]
20. Acute dialysis: PMN-elastase as a new parameter for controlling individual anticoagulation with low molecular weight heparin (Fragmin).
Swars H; Hafner G; Weilemann LS; Ehrenthal W; Schinzel H; Prellwitz W; Meyer J
Intensive Care Med; 1991; 17(1):52-6. PubMed ID: 1645379
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
